HIV therapy最新文献_第9页

Future treatment for non-AIDS-defining cancers in HIV-infected patients 艾滋病毒感染患者非艾滋病定义癌症的未来治疗

HIV therapy Pub Date : 2009-07-06 DOI: 10.2217/HIV.09.14

J. Deeken, L. Pantanowitz, B. Dezube

{"title":"Future treatment for non-AIDS-defining cancers in HIV-infected patients","authors":"J. Deeken, L. Pantanowitz, B. Dezube","doi":"10.2217/HIV.09.14","DOIUrl":"https://doi.org/10.2217/HIV.09.14","url":null,"abstract":"ISSN 1758-4310 10.2217/HIV.09.14 © 2009 Future Medicine Ltd HIV Ther. (2009) 3(4), 311–314 at higher risk for some cancers compared with African–Americans and patients of other ethnic groups [7]. Additional risk factors include behavioral aspects, such as an increased use of tobacco and alcohol in patients with HIV [8]. Research has demonstrated that HIV itself may have direct effects that contribute to the development of NADC. For example, the HIV Tat protein may cause transactivation of protooncogenes [9]. Other genes within the HIV virus may inhibit tumor suppressor genes, including p53. HIV infection may cause microsatellite gene instability and genetic alterations leading towards onco genesis. Tissue infection with HIV may make these t issues more sensitive to the effects of carcinogens from the environment. Finally, HIV infection can cause endothelial abnormalities including pro angiogenesis, which may enhance the development of tumor growth and metastasis [1]. There have been conflicting data regarding whether HAART is associated with the risk of developing NADCs. Some studies have demonstrated a decreased risk of developing a NADC while patients are on HAART, compared with patients who are not receiving antiretroviral therapy or are only on single agent or dual agent antiretroviral therapy [7]. Other studies have demonstrated a possible increased risk if patients are on HAART [4], and specifically if they are on a non-nucleoside reverse transcriptase inhibitorbased therapy [5]. A concerning, recent finding in the large Phase III trial that led to the approval of raltegravir (an integrase inhibitor also known as Isentress [Merck] and MK-0518) was that during the period of the study, patients on raltegravir had a higher risk of developing a NADC compared with those taking placebo [10]. Clearly more research is needed to elucidate the role of antiretroviral therapy, immune reconstitution and the relative risk of developing NADCs. Editorial","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"37 1","pages":"311-314"},"PeriodicalIF":0.0,"publicationDate":"2009-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83374328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Managing HIV therapy literacy in resource-limited settings 在资源有限的环境中管理艾滋病毒治疗知识

HIV therapy Pub Date : 2009-07-06 DOI: 10.2217/HIV.09.16

S. Sahay, M. Ghate, S. Mehendale

引用次数: 8

Tesamorelin: a synthetic growth hormone-releasing factor analog for the treatment of HIV-associated lipodystrophy 替沙莫林:一种用于治疗hiv相关脂肪营养不良的合成生长激素释放因子类似物

HIV therapy Pub Date : 2009-07-06 DOI: 10.2217/HIV.09.24

Ying Wang, B. Tomlinson

引用次数: 0

Monitoring HIV drug resistance in treatment-naive individuals: molecular indicators, epidemiology and clinical implications. 监测HIV耐药性在治疗初期个体:分子指标，流行病学和临床意义。

HIV therapy Pub Date : 2009-07-06 DOI: 10.2217/HIV.09.23

E. Magiorkinis, M. Detsika, A. Hatzakis, D. Paraskevis

引用次数: 5

Future directions in the treatment of HIV-HBV coinfection. HIV-HBV合并感染治疗的未来方向。

HIV therapy Pub Date : 2009-07-01 DOI: 10.2217/hiv.09.19

David M Iser, Sharon R Lewin

引用次数: 8

Clinical implications of new findings in HIV basic research. HIV基础研究新发现的临床意义。

HIV therapy Pub Date : 2009-07-01 DOI: 10.2217/hiv.09.20

Manish Sagar

引用次数: 2

Type I interferon in HIV treatment: from antiviral drug to therapeutic target. I 型干扰素在 HIV 治疗中的应用：从抗病毒药物到治疗目标。

HIV therapy Pub Date : 2009-05-01 Epub Date: 2009-04-30 DOI: 10.2217/hiv.09.8

Adriano Boasso

引用次数: 0

HIV/AIDS in private sector companies: cost impacts and responses in southern Africa 私营部门公司的艾滋病毒/艾滋病:南部非洲的成本影响和对策

HIV therapy Pub Date : 2009-04-30 DOI: 10.2217/HIV.09.10

G. George, J. Gow, A. Whiteside

引用次数: 19

Pediatric adherence to antiretroviral therapy in resource-poor settings: challenges and future perspectives 资源贫乏环境下儿童抗逆转录病毒治疗依从性:挑战和未来展望

HIV therapy Pub Date : 2009-04-30 DOI: 10.2217/HIV.09.2

F. Pérez, V. Leroy

{"title":"Pediatric adherence to antiretroviral therapy in resource-poor settings: challenges and future perspectives","authors":"F. Pérez, V. Leroy","doi":"10.2217/HIV.09.2","DOIUrl":"https://doi.org/10.2217/HIV.09.2","url":null,"abstract":"The HIV pediatric epidemic in low-income countries is still growing with an increasing impact on children. By the end of 2007, more than 2 million children under 15 years of age worldwide were living with HIV, 90% in subSaharan Africa. In that year alone, 370,000 children were newly infected and 270,000 died. AIDS has become one of the leading causes of mortality among children under the age of 5 years in developing countries [101]. In the absence of combination antiretroviral therapy (cART), 52% of children infected with perinatally acquired HIV infection will die by the age of 2 years [1]. Numerous studies have confirmed the clinical efficacy and feasibility of cART in HIVinfected adults in Africa [2,3] but, to date, resources and programs targeting HIV-infected children in resource-poor settings remain limited. Even though the use of cART to treat children has increased in recent years in subSaharan Africa, less than 15% of children needing cART in Africa currently receive it [102]. It is estimated that more than 780,000 children are in need of cART in lowand middle-income countries [103]. When made accessible, treatment for children in this context has proved highly effective [4]. Studies have found the survival probability at 12 months for children on cART to be more than 95% in settings in sub-Saharan Africa [5] and Asia [6]. Education and adherence counseling are therefore essential components of cART and adherence in HIV-infected children is critical to the success of cART.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"159 1","pages":"213-219"},"PeriodicalIF":0.0,"publicationDate":"2009-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77902638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Promising novel compounds for the generation of new anti-HIV-RT therapeutic drugs 有希望的新化合物产生新的抗hiv - rt治疗药物

HIV therapy Pub Date : 2009-04-30 DOI: 10.2217/HIV.09.3

T. M. Souza, Carlos Frederico Leite Fontes

引用次数: 0